Zai Lab (ZLAB) Expected to Announce Quarterly Earnings on Thursday

Zai Lab (NASDAQ:ZLAB) is projected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Zai Lab to announce earnings of ($0.6794) per share and revenue of $103.8660 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings results on Wednesday, April 1st. The company reported ($0.50) earnings per share (EPS) for the quarter. Zai Lab had a negative return on equity of 24.32% and a negative net margin of 39.29%.The business had revenue of $99.61 million for the quarter. On average, analysts expect Zai Lab to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zai Lab Stock Performance

NASDAQ:ZLAB opened at $18.49 on Wednesday. The stock has a market cap of $2.10 billion, a price-to-earnings ratio of -11.41 and a beta of 0.78. Zai Lab has a 1 year low of $15.96 and a 1 year high of $39.64. The business has a fifty day moving average of $18.60 and a 200-day moving average of $19.21.

Insider Activity at Zai Lab

In other Zai Lab news, CEO Ying Du sold 50,000 shares of the company’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $20.09, for a total value of $1,004,500.00. Following the completion of the sale, the chief executive officer directly owned 1,122,626 shares of the company’s stock, valued at approximately $22,553,556.34. This represents a 4.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Yajing Chen sold 2,264 shares of the company’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $17.46, for a total transaction of $39,529.44. Following the completion of the sale, the chief financial officer directly owned 35,691 shares of the company’s stock, valued at $623,164.86. The trade was a 5.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 90,873 shares of company stock valued at $1,730,096 over the last 90 days. 4.88% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zai Lab

An institutional investor recently raised its position in Zai Lab stock. Royal Bank of Canada increased its holdings in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,771 shares of the company’s stock after purchasing an additional 9,390 shares during the quarter. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 at the end of the most recent quarter. Institutional investors own 41.65% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ZLAB shares. Zacks Research raised shares of Zai Lab from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Weiss Ratings raised shares of Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 29th. Wall Street Zen downgraded shares of Zai Lab from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Citigroup reduced their price target on shares of Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a research note on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $40.00.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.